Search results

731 results

Sorted by Relevance . Sort by Date

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
NICE guidelines Remove NICE guidelines filter
Clinical guidelines Remove Clinical guidelines filter
Medical technologies guidance Remove Medical technologies guidance filter
Social care guidelines Remove Social care guidelines filter
Medicines practice guidelines Remove Medicines practice guidelines filter

Gefapixant for treating refractory or unexplained chronic cough [ID3789]

Proposed [GID-TA10678] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Foslevodopa-foscarbidopa for treating Parkinson's disease with motor fluctuations [ID3876]

Proposed [GID-TA10772] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

Proposed [GID-TA10752] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Risankizumab for previously treated active psoriatic arthritis [ID1399]

Proposed [GID-TA10819] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]

Proposed [GID-TA10820] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Romosozumab for treating severe osteoporosis [ID3936]

Proposed [GID-TA10828] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID3896]

Proposed [GID-TA10812] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Stye: antimicrobial prescribing

In development [GID-NG10167] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Blepharitis: antimicrobial prescribing

In development [GID-NG10168] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Conjunctivitis: antimicrobial prescribing

In development [GID-NG10166] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Vaccine uptake in the general population

In development [GID-NG10139] Expected publication date: 06 April 2022

Type

NICE guideline

Status

In development
Managing common infections - antimicrobial prescribing guidelines

In development [GID-NG10050] Expected publication date: TBC

Type

NICE guideline

Status

In development
Skin abscess: antimicrobial prescribing

In development [GID-NG10163] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
SACT

In development [GID-NG10184] Expected publication date: TBC

Type

NICE guideline

Status

In development
Mental wellbeing at work

In development [GID-NG10140] Expected publication date: 15 December 2021

Type

NICE guideline

Status

In development
Reducing sexually transmitted infections

In development [GID-NG10142] Expected publication date: 09 February 2022

Type

NICE guideline

Status

In development
Clostridioides difficile infection: antimicrobial prescribing

In development [GID-NG10144] Expected publication date: 23 July 2021

Type

Antimicrobial prescribing guideline

Status

In development
Social, emotional and mental wellbeing in primary and secondary education

In development [GID-NG10125] Expected publication date: 06 July 2022

Type

NICE guideline

Status

In development
Integrated health and social care for people experiencing homelessness

In development [GID-NG10170] Expected publication date: 16 March 2022

Type

NICE guideline

Status

In development
Tobacco: preventing uptake, promoting quitting and treating dependence (update)

In development [GID-NG10086] Expected publication date: TBC

Type

NICE guideline

Status

In development
Looked-after children and young people

In development [GID-NG10121] Expected publication date: 20 October 2021

Type

NICE guideline

Status

In development
Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712]

In development [GID-TA10572] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]

In development [GID-TA10342] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]

In development [GID-TA10024] Expected publication date: 28 June 2017

Type

Technology appraisal guidance

Status

In development
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

In development [GID-TA10046] Expected publication date: 22 November 2017

Type

Technology appraisal guidance

Status

In development
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]

In development [GID-TA10633] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683

In development [GID-TA10537] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer [ID1465]

In development [GID-TA10352] Expected publication date: 13 October 2021

Type

Technology appraisal guidance

Status

In development
Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]

In development [GID-TA10656] Expected publication date: 02 March 2022

Type

Technology appraisal guidance

Status

In development
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

In development [GID-TAG363] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy [ID1518]

In development [GID-TA10504] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

In development [GID-TA10607] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]

In development [GID-TA10589] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

In development [GID-TA10573] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab-relatlimab for untreated advanced or metastatic melanoma [ID1688]

In development [GID-TA10581] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

In development [GID-TA10583] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]

In development [GID-TA10571] Expected publication date: 25 August 2021

Type

Technology appraisal guidance

Status

In development
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 3 therapies [ID2701]

In development [GID-TA10568] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]

In development [GID-TA10616] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]

In development [GID-TA10617] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

In development [GID-TA10522] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Elotuzumab for multiple myeloma [ID966]

In development [GID-TA10134] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

In development [GID-TA10429] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

In development [GID-TA10542] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260

In development [GID-TA10309] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ibrutinib for untreated mantle cell lymphoma (ID1221)

In development [GID-TA10185] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289

In development [GID-TA10210] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

In development [GID-TA10326] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]

In development [GID-TA10252] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]

In development [GID-TA10223] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development